T cells secrete bioactive exosomes (EXO), but the potential immunoregulatory effect of T-cell EXO is largely unknown. In this study, we generated activated ovalbumin (OVA)-specific CD4 1 T cells in vitro via coculture of OVA-pulsed dendritic cells (DC OVA ) with naive CD4 1 T cells derived from OVA-specific T-cell receptor (TCR) transgenic OTII mice. CD4 1 T-cell EXO were then purified from the CD4 1 T-cell culture supernatants by differential ultracentrifugation. CD4
INTRODUCTION
Exosomes (EXO) are small membrane vesicles (50-100 nm in diameter) of endocytic origin that are formed by the fusion of multivesicular endosomes (MVE) with the plasma membrane, followed by exocytosis.
1 EXO can be constitutively or inductively secreted by a variety of cell types, such as dendritic cells (DCs), macrophages, T cells, B cells, reticulocytes, mastocytes and tumor cells. 2 Extensive studies have shown that DC-and tumor cell-released EXO can trigger strong tumor-specific CD8 1 cytotoxic T lymphocyte (CTL) responses and antitumor immunity. [3] [4] [5] [6] [7] Thus, DC-and tumor cell-derived EXO are attractive molecules for immunotherapy and have been used for antitumor vaccines.
Activated T cells can release bioactive EXO-bearing TCR/CD3 complexes, 8 Fas ligand (FasL) and APO2 ligand, 9 which are implicated in immune regulation via the induction of activation-induced cell death of T cells. 10 In addition, T-cell EXO can be taken up by DCs or B cells by intercellular molecule transfer from T cells to antigen-presenting cells (APCs), leading to modulation of the APC and regulation of Tcell responses. 11 However, the potential effect of activated T-cell EXO on modulation of DC-induced immune responses is still largely unclear.
In this study, we activated CD4 1 T cells derived from OVA-specific T-cell receptor (TCR) transgenic OTII mice 12 in vitro with ovalbumin (OVA)-pulsed dendritic cells (DC OVA ) and purified EXO from culture supernatants of the CD4 1 T cells by differential ultracentrifugation. We assessed the effect of EXO on DC OVA -mediated CD8
1 CTL responses and antitumor immunity. We found that DC OVA took up CD4 1 T-cell EXO bearing the OVA-specific TCR and lymphocyte function associated antigen-1 (LFA-1) via peptide/major histocompatibility complex (pMHC) II/TCR and CD54/LFA-1 interactions. We demonstrated that OVA-specific CD4
1 T-cell EXO, but not ConA-stimulated polyclonal CD4
1 T-cell EXO from C57BL/6 mice, inhibited in vitro DC OVA -stimulated CD4
1 T-cell proliferation and in vivo CD8
1 CTL responses and antitumor immunity against OVAexpressing B16 melanoma BL6-10 OVA cells. In addition, EXO derived from the T-cell hybridoma cell line MF72.2D9 expressing an OVAspecific CD4
1 TCR had an inhibitory effect similar to that of OTII CD4
1 T-cell EXO on CD8 1 CTL-mediated antitumor immunity. Center, Worcester, MA, USA). The highly lung metastatic B16 mouse melanoma (BL6-10) and OVA-transfected BL6-10 (BL6-10 OVA ) cell lines were generated in our laboratory. 12 Female C57BL/6 (B6, H-2K b ) mice were obtained from Charles River Laboratories (St Laurent, Que., Canada). The OVA 323-339 -specific TCR-transgenic (OTII) mice on a C57BL/6 background were obtained from the Jackson Laboratory (Bar Harbor, MA, USA). All mice were housed in the animal facility at the Saskatoon Cancer Center. All animal experiments were performed in accordance with the Canadian Council for Animal Care guidelines.
MATERIALS AND METHODS

Reagents, cell lines and animals
Preparation of EXO
OVA-pulsed bone marrow-derived dendritic cells (DC OVA ) from C57BL/6 mice were generated in the presence of GM-CSF/IL-4 (20 ng/ml) and pulsed with OVA protein (0.1 mg/ml) overnight, as previously described. 12 To generate activated OVA-specific CD4 1 T cells, naive CD4
1 T cells (4310 5 cells/ml) from OTII mice were stimulated for 72 h with irradiated (4000 rad) DC OVA (1310 5 cells/ml) in the presence of IL-2 (20 U/ml). 12 The OVA-specific CD4 1 T cells were incubated with or without 0.5 mM carboxyfluorescein diacetate succinimidyl ester (CFSE) and then cultured in serum-free AIM-V medium (Invitrogen Corp., Carlsbad, CA, USA) with IL-2 (20 U/ ml) for 24 h. EXO were purified from the T-cell culture supernatants by differential ultracentrifugation, and protein content was quantified by Bradford assay. 13 DC OVA -activated OTII CD4 1 T cell-released EXO and CFSE-labeled OTII CD4
1 T cell-released EXO were termed EXO and EXO CFSE , respectively. EXO derived from the T-cell hybridoma cell line MF72.2D9 expressing an OVA-specific CD4 1 TCR were termed EXO MF , and EXO generated from ConA-stimulated C57BL/6 CD4 1 T cells were used as control EXO (EXOcont).
Electron microscopic analysis EXO samples were fixed in 4% paraformaldehyde and then loaded onto carbon-coated formvar grids. After incubation in a moist atmosphere for 20 min, the samples were washed twice in phosphatebuffered saline (PBS) and then fixed for 5 min in 1% glutaraldehyde. After three washes, the EXO sample-loaded grids were stained for 10 min with saturated aqueous uranyl. EXO samples were then examined with a Zeiss EM10C electron microscope at 60 kV. , CD11c, CD40, CD54, CD80, pMHC I, Fas and FasL and analyzed by flow cytometry as described previously. 13 EXO samples (10 g/100 ml PBS) were incubated with FITC-Abs (2 ml, 1 mg/ml) specific for CD4, Vb5.1, 5.2 TCR, LFA-1, CD25 and FasL on ice for 30 min and then analyzed by flow cytometry. 13 EXO were first gated using calibrated polystyrene latex microbeads (3.8 mm) bound to fluorescent dyes (Sigma, St Louis, MO, USA) and analyzed for expression of the above molecules by flow cytometry.
Uptake of EXO by DCs
For assessment of exosomal uptake, DC OVA were incubated with CFSE-EXO (10 mg/1310
6 DC OVA cells) in serum-free AIM-V medium at 37 uC for 4 h, washed with PBS and then analyzed for CFSE expression by flow cytometry and confocal fluorescence microscopy. To examine the molecular mechanism involved in EXO uptake, DC OVA were incubated with a panel of Abs specific for H-2K b , Ia b and LFA-1 on ice before and during coculture with CFSE-EXO in AIM-V medium at 37 uC for 4 h. After being washed with PBS, the CFSE-positive cells were detected and counted by confocal fluorescence microscopy.
T-cell proliferation assay
To assess in vitro CD4
1 T-cell proliferation, purified naive CD4 1 T cells (0.4310 5 cells/well) from OTII mice were incubated with serial dilutions of irradiated (4000 rad) DC OVA (0.1310 5 cells/well) in the absence or presence of different concentrations (1, 5 and 20 mg/ml) of EXO or EXOcont. After incubation for 48 h, CD4
1 T-cell proliferation was measured by adding 1 mCi 3 H-thymidine (1 mCi/ml; GE Healthcare, Waukesha, WI, USA) to each well. After overnight incubation, 3 H-thymidine incorporation was determined by liquid scintillation counting. For the in vivo CD8
1 T-cell proliferation assay, C57BL/6 mice (eight mice per group) were immunized intravenously (i.v.) with DC OVA (1310 6 cells/mouse) alone or together with OTII CD4 1 T-cell EXO, EXOcont or EXO MF (30 mg/mouse). Six days later, cells from tail blood samples of immunized mice were stained with a PE-H-2K b /OVAI tetramer and FITC-anti-CD8 Ab according to the manufacturer's protocol and analyzed by flow cytometry. 12 
Cytotoxicity assay
To assess killing activity of DC OVA -induced CD8
1 CTL, C57BL/6 mice were immunized i.v. with DC OVA (1310 6 cells/mouse), alone or together with OTII CD4 1 T-cell EXO, EXOcont or EXO MF (30 mg/ mouse). Spleen cells from C57BL/6 mice pulsed with OVAI peptide were labeled with a high concentration of CFSE (CFSE high , 3.0 mM) and served as OVA-specific target cells, whereas spleen cells pulsed with the irrelevant Mut1 peptide were labeled with a low concentration of CFSE (CFSE low , 0.6 mM) and served as nonspecific target cells. Six days later, the immunized mice were then injected i.v. with a 1 : 1 
Statistical analysis
Student's t test was used for a comparison of variables from different groups in both in vitro and in vivo experiments, and a log rank test was used for comparison of animal survival in different groups. Statistical analyses were performed using Prism software (GraphPad Software, Inc., San Diego, CA, USA).
14 P values of ,0.05 were considered significant.
RESULTS
T-cell EXO express CD4
1 T-cell molecules, such as CD4, TCR, LFA-1, CD25 and FasL In vitro DC OVA -stimulated CD4
1 T cells derived from OVA-specific TC-transgenic OTII mice expressed CD4, Vb5.1, 5.2 TCR and CD25 (Figure 1a ), indicating that they were OVA-specific CD4 1 T cells.
They also expressed the T-cell adhesion molecule, LFA-1 and FasL. EXO released from in vitro DC OVA -stimulated OTII CD4 1 T cells and ConA-stimulated polyclonal CD4
1 T cells derived from wild-type C57BL/6 mice were purified by differential ultracentrifugation and termed EXO and EXOcont, respectively. These EXO were then subjected to analysis by electron microscopy, flow cytometry and western blot. As shown in Figure 1b , EXO had a typical exosomal 'saucer' or round shape with a diameter between 50 and 100 nm. Flow cytometric analysis showed that OTII CD4
1 T-cell EXO expressed T-cell markers (CD4, Vb5.1, 5.2 TCR, LFA-1, CD25 and FasL), but to a much lesser extent than OTII CD4
1 T cells (Figure 1a) . Except for Vb5.1, 5.2 TCR expression, EXOcont had a similar phenotype as OTII CD4
1 T cellreleased EXO (data not shown). We also demonstrated that EXOassociated proteins, including LAMP-1, TCR and LFA-1, were abundant, but no apoptotic marker, including Calnexin, 15 was found in OTII CD4
1 T-cell EXO by western blot analysis (Figure 1c ), indicating that apoptotic vesicles were absent in the EXO samples. In addition, ConAstimulated polyclonal C57BL/6 CD4 1 T cell-released EXOcont had a similar morphological and biochemical profile as OTII CD4
1 T-cell EXO, and EXOcont also contained EXO-associated proteins, such as LAMP-1 and LFA-1, but not Vb5.1, 5.2 TCR or Calnexin (data not shown).
DCs take up T-cell EXO via pMHC II/TCR and CD54/LFA-1 interactions DCs can take up T-cell EXO. To assess whether T-cell EXO could be taken up by DCs, DC OVA were incubated with CFSE-labeled OTII CD4
1 T cell-released EXO (CFSE-EXO or EXO CFSE ) for 4 h and then analyzed by flow cytometry and confocal fluorescence microscopy. As 1 TCR.
shown in Figure 2a and b, DC OVA expressed CFSE after incubation with CFSE-EXO, but not with CFSE-EXOcont, indicating that DC OVA took up OTII CD4 1 T-cell EXO. To assess the molecular mechanism of uptake of CD4 1 T-cell EXO by DC OVA , we added blocking reagents to the above mixture of DC OVA and EXO CFSE , and CFSE-positive DC OVA cells with EXO CFSE uptake were further assessed by confocal fluorescence microscopy. We found that both anti-Ia b and anti-LFA-1 Abs, but not the control anti-H-2K b Ab, significantly inhibited the uptake of EXO CFSE by DC OVA (P,0.05) (Figure 2c ), indicating that both pMHC II/TCR and CD54/LFA-1 interactions mediated DC OVA uptake of CD4 1 T-cell EXO.
T-cell EXO inhibit in vitro CD4 1 T-cell proliferation
Bone marrow-derived DC OVA from C57BL/6 mice expressed CD11c, CD40, CD80 and Ia b (Figure 3a) , indicating that they were mature DCs. In addition, DC OVA expressed CD54, the pMHC I and Fas. To assess the potential effect of T-cell EXO, we performed an in vitro DC OVA -stimulated CD4
1 T-cell proliferation assay. We found that DC OVA efficiently stimulated OTII CD4
1 T-cell proliferation (Figure 3b ), whereas OTII CD4 1 T-cell EXO, but not polyclonal CD4
1 T-cell EXOcont, significantly inhibited DC OVA -mediated CD4
1 T-cell proliferation (P,0.05) in a dose-dependent manner (Figure 3c ). However, OTII CD4
1 T-cell EXO did not inhibit in vitro CD3/28-mediated T-cell proliferation (data not shown). OTII CD4 (Figure 3d ), indicating that EXO had no direct ability to kill naive CD4 1 T cells, and the reduced T-cell proliferation seen in Figure 3c was therefore not due to the killing activity of EXO.
T-cell EXO did not induce Annexin V (an apoptosis marker) expression in naive T cells, whereas irradiation did
T-cell EXO suppress in vivo OVA-specific CD8
1 CTL responses and antitumor immunity DC OVA also stimulated in vivo OVA-specific CD8 1 T-cell responses, as detected by FITC-CD8 and PE-tetramer staining in wild-type C57BL/ 6 mice ( Figure 4 ). However, they failed to stimulate CD8 1 T-cell responses in Ia b2/2 mice lacking CD4 1 T cells, indicating that the CD8 1 CTL responses were CD4 1 T cell dependent. To assess whether T-cell EXO could suppress in vivo DC OVA -activated CD4 1 T celldependent CD8
1 CTL responses, we immunized C57BL/6 mice i.v. with DC OVA alone or DC OVA together with T-cell EXO. As shown in Figure 5a , DC OVA stimulated 1.58% of tetramer-positive CD8 1 T cells from the total CD8 1 T-cell population in the blood at day 6 after immunization. However, co-immunization of DC OVA with OTII CD4 1 T-cell EXO, but not with polyclonal CD4 1 T-cell EXOcont, stimulated 0.62% of tetramer-positive CD8 1 T cells from the total CD8 1 T-cell population (P,0.05), indicating that OTII CD4 1 T-cell EXO expressing an OVA-specific TCR significantly inhibited DC OVAinduced OVA-specific CD8 1 T-cell responses. To assess the effector function of OVA-specific CD8
1 T cells, we adoptively transferred OVAI peptide-pulsed splenocytes that had been labeled with CFSE high as well as Mut1 control peptide-pulsed splenocytes that had been labeled with CFSE low (1 : 1) into recipient mice that had been vaccinated with DC OVA or DC OVA plus EXO. We then analyzed loss of OVAI-specific CFSE high target cells in the recipient mice, which represented the killing activity of OVA-specific effector CD8
1 CTLs in the recipient mice. As shown in Figure 5b , no CFSE high target cell loss was observed in mice immunized with PBS. As expected, there was a substantial loss (81.3%) of OVA-specific target (CFSE high ) cells in mice immunized with DC OVA , indicating that DC OVA induced CD8 1 T-cell differentiation into OVA-specific CTL effectors in vivo. Similar to the 1 T-cell EXO (30 mg/ml) in DMEM plus 10% FCS and IL-2 (20 U/ml), or irradiated (2000 rad) naive OTII CD4 1 T cells were cultured in DMEM plus 10% FCS and IL-2 (20 U/ml) for 8 h (solid line). T cells were then harvested and stained with FITC-Annexin V for flow cytometric analysis. One representative experiment of three is shown. Ab, antibody; DC OVA , OVA-pulsed dendritic cell; DMEM, Dulbecco's modified Eagle's medium; EXO, exosomes; EXOcont, control EXO; FCS, fetal calf serum; FITC, fluorescein isothiocyanate.
T-cell EXO inhibited antitumor immunity, C57BL/6 mice were immunized i.v. with DC OVA or DC OVA plus EXO. Eight days later, the immunized mice were challenged subcutaneously with BL6-10 OVA tumor cells. As shown in Figure 5c , all the mice injected with PBS died from the malignancy within 21 days after tumor cell challenge. The DC OVA vaccine protected 8/8 (100%) mice from tumor growth. However, DC OVA plus OTII CD4 1 T-cell EXO, but not DC OVA plus EXOcont, significantly inhibited DC OVA -mediated immune protection against OVA-expressing BL6-10 OVA tumors, with 5/8 surviving mice (P,0.05), indicating that OTII CD4
1 T-cell EXO also inhibited OVA-specific antitumor immunity.
T-cell hybridoma-released EXO similarly inhibit DC-stimulated CD8
1 CTL responses and antitumor immunity EXO derived from the T-cell hybridoma cell line, MF72.2D9, expressing an OVA-specific CD4 1 TCR (EXO MF ), were purified from culture supernatants by differential ultracentrifugation. The EXO MF were then phenotypically characterized by electron microscopy, western blot and flow cytometry. As shown in Figure 1b , EXO MF had a typical exosomal 'saucer' or round shape with a diameter between 50 and 100 nm. We also confirmed that LAMP-1, Vb5.1, 5.2 TCR and LFA-1 were expressed in EXO MF samples (Figure 1c ). In addition, EXO MF expressed T-cell markers (Vb5.1, 5.2 TCR, LFA-1 and FasL), but to a much lesser extent than MF72.2D9 hybridoma cells (data not shown). To assess its inhibitory effect, EXO MF released from MF72.2D9 hybridoma cells were further used in in vivo experiments as described above. We found that MF72.2D9 T-cell hybridoma-derived EXO MF expressing an OVA-specific CD4
1 TCR also inhibited DC OVA -stimulated OVA-specific CD8
1 CTL responses (Figure 5a and b) and antitumor immunity against BL6-10 OVA tumor cells (Figure 5c ). This result indicated that EXO MF had a similar inhibitory effect as OTII CD4
1 T-cell EXO on in vivo DC OVA -induced OVA-specific CD8
1 CTL responses and antitumor immunity.
DISCUSSION
The exchange of plasma membrane components between immune cells is common during cellular encounters, and this activity could play an important role in physiologic, pathologic and therapeutic settings. 18, 19 The detailed mechanisms of trogocytosis have yet to be elucidated, but likely require contact between donor and acceptor cells and formation of an immunologic synapse. 20, 21 Surface molecule transfer has been predominantly reported for the transfer of DC surface molecules to T cells in a unidirectional manner. 22, 23 As a result, T cells with acquired DC molecules have been shown to be either immunogenic 12, 24 or tolerogenic 25, 26 in their effect on immune responses. In addition, T cells with uptake of DC-released EXO have been used as T-cell vaccines for stimulation of antitumor immunity. 22, 27 Recently, we have shown that molecular transfer between DCs and T cells is bidirectional, and DCs can also acquire T-cell molecules via a dissociation-associated pathway. 28 It has recently been reported that transfer of T-cell molecules to DCs occurs when DCs activate CD4
1 T cells via two distinct mechanisms, including an early antigen-independent mechanism of T-cell activation and a late antigen-specific mechanism of T-cell activation. 29 The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of accessory cells. 30 Another potential mechanism for trogocytosis is via exosome fusion to acceptor cells or internalization and recycling of exosomal molecules on the acceptor cells. 31 The exosomal molecules on acceptor cells are quite stable and can last as long as 12 days in culture. 32 Activated T cells can also secrete bioactive EXO, [8] [9] [10] which can be taken up by DCs or B cells via direct intercellular molecule transfer from T cells to APCs. 11 However, the potential effect of T-cell EXO on the regulation of immune responses is not clear.
In this study, we demonstrated that activated CD4 1 T cells secreted EXO-expressing T-cell markers and that DCs took up CD4
1 T-cell EXO via pMHC II/TCR and CD54/LFA-1 interactions. OVA-specific CD4
1 T-cell EXO from OTII transgenic mice, but not ConA-stimulated polyclonal CD4
1 T-cell EXO from wild-type C57BL/6 mice, inhibited OVA-specific DC-stimulated in vitro CD4
1 CTL responses and antitumor immunity against OVA-expressing B16 melanoma BL6-10 OVA cells. DCs receiving TCR molecules are less efficient at priming T-cell responses, possibly because the transferred TCR molecule mask antigen-bearing MHCs and consequently reduce their accessibility to antigen-specific T cells. 29 It has also been demonstrated that pMHC I expression on DCs can be downregulated after interaction with antigen-specific CD8 1 T cells via the TCR-mediated internalization pathway. 20, 33 In addition, FasL-expressing tumor cell-released EXO can induce T-cell apoptosis via the Fas/FasL pathway. [34] [35] [36] In our study, OTII CD4 1 Tcell EXO bearing an OVA-specific TCR and expressing FasL specifically inhibited DC OVA -mediated CD4 1 T-cell stimulation, and this may be associated with the downregulation or masking of the pMHC II on DC OVA by CD4 1 T-cell EXO and induction of apoptosis in Fasexpressing DC OVA cells via the Fas/FasL pathway. Importantly, we also demonstrated that EXO derived from the T-cell hybridoma cell line, MF72.2D9, expressing an OVA-specific CD4
1 TCR had a similar inhibitory effect as OTII CD4
1 T-cell EXO on CD8 1 CTL-mediated antitumor immunity. Autoimmune diseases and rejection of transplanted organs are mainly mediated by DC-induced cellular CTL responses. 37, 38 Antigen-specific T-cell EXO derived from immortal tumor cell lines, engineered to express both antigen-specific TCRs and FasL, could thus be used as a new type of immunosuppressive reagent to inhibit autoimmune diseases and prolong organ transplantation by masking or killing the antigen-bearing DC.
Taken together, our data demonstrate that antigen-specific T cellsecreted EXO inhibit antigen-specific CD8
1 CTL responses and thus indicate that antigen-specific T-cell EXO might be used as a new type 
